Persistent proteinuria among a cohort of Nigerian children with sickle cell anaemia

一组患有镰状细胞贫血症的尼日利亚儿童出现持续性蛋白尿

阅读:1

Abstract

BACKGROUND: Persistent proteinuria is an early and modifiable marker of kidney damage. Although Nigeria has the highest burden of sickle cell anaemia (SCA) globally, the prevalence of proteinuria is unknown largely because many of the studies only determined proteinuria in a single urine sample or used less sensitive methods, such as dipstick. Unlike dipstick screening, quantitative urine protein-creatinine ratio allows more accurate detection of low-grade proteinuria. OBJECTIVES: To determine the prevalence and determinants of persistent proteinuria among children with SCA. METHODS: Children with SCA and age and sex-matched controls attending a publicly funded hospital in central Nigeria were consecutively enrolled. Proteinuria was determined at the first visit using the spot urine protein creatinine ratio and repeated at least 3 months afterwards for those with proteinuria. In addition, serum creatinine, full blood count, and fetal hemoglobin were determined at the first visit. Persistent proteinuria was defined as a urine protein-to-creatinine ratio ≥0.2 at both visits over a follow-up period of at least 3 months. Participants were classified based on the presence or absence of persistent proteinuria, and baseline characteristics were compared using within-group distributions for categorical variables with appropriate statistical tests. RESULTS: One hundred and forty-nine children, each with SCA and controls, were enrolled, respectively. The median (IQR) age of the study participants was 9.0 (6.0) years for both groups, with 65% being males. Persistent proteinuria occurred in 35 (23.5%) children with SCA versus 4 (2.7%) controls (p-value < 0.01). Children with persistent proteinuria had a lower level of fetal hemoglobin. (adjusted OR 0.583, 95% C.I 0.473-0.719). CONCLUSION: About a quarter of children with SCA had persistent proteinuria, an early and modifiable marker of chronic kidney disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。